logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Asthma

    Medications for Asthma

    FiltersReset Filters
    69 results

    • advair

      (fluticasone propionate and salmeterol)
      GlaxoSmithKline LLC
      Usage: ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 and older and for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or for patients not adequately controlled on long-term asthma medications.

    • albuterol sulfate

      (Albuterol Sulfate)
      Nephron Pharmaceuticals Corporation
      Usage: Albuterol inhalation solution is indicated for relieving bronchospasm in patients aged 2 to 12 with asthma, a condition characterized by reversible obstructive airway disease.

    • albuterol sulfate inhalation solution

      (Albuterol Sulfate)
      Ritedose Pharmaceuticals, LLC
      Usage: Albuterol Sulfate Inhalation Solution is indicated for relieving bronchospasm in patients aged 2 to 12 years with asthma (reversible obstructive airway disease).

    • alvesco

      (ciclesonide)
      Covis Pharma US, Inc
      Usage: ALVESCO is indicated for the maintenance treatment of asthma in adults and pediatric patients aged 12 and older. It is not intended for the relief of acute bronchospasm or for children under 12 years of age.

    • arnuity ellipta

      (fluticasone furoate)
      GlaxoSmithKline LLC
      Usage: ARNUITY ELLIPTA is indicated for the maintenance treatment of asthma in adults and children aged 5 years and older, but is not intended for the relief of acute bronchospasm.

    • asmanex hfa

      (MOMETASONE FUROATE)
      Organon LLC
      Usage: ASMANEX® HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older. It is not intended for relief of acute bronchospasm.

    • budesonide

      (Budesonide)
      Cipla USA Inc.
      Usage: Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and prophylactic therapy in children aged 12 months to 8 years. It is not intended for the relief of acute bronchospasm.

    • budesonide

      (Budesonide)
      Sandoz Inc
      Usage: Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and prophylactic therapy in children aged 12 months to 8 years. It is not intended for the relief of acute bronchospasm.

    • budesonide

      (Budesonide)
      Sun Pharmaceutical Industries, Inc.
      Usage: Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and prophylactic therapy in children aged 12 months to 8 years. It is not intended for the relief of acute bronchospasm.

    • budesonide

      (Budesonide)
      Teva Pharmaceuticals USA, Inc.
      Usage: Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and prophylactic therapy in children aged 12 months to 8 years. It is not intended for the relief of acute bronchospasm.
      • ...